CAL102

CAL102 is a monoclonal antibody developed by Calluna Pharma that neutralizes oxidised phospholipids. Oxidised phospholipids are implicated in the onset and progression of a wide range of acute and chronic inflammatory and fibrotic diseases. By targeting these molecules, CAL102 aims to disrupt disease-associated downstream signaling pathways involved in inflammation and tissue fibrosis, while maintaining a favorable safety profile. The drug has demonstrated efficacy in several preclinical disease models focused on immunological diseases driven by acute or chronic inflammation and non-resolving tissue fibrosis[1][2].